| Literature DB >> 23437245 |
C Rebecca North1, T Cam Wild, Lonnie Zwaigenbaum, Ian Colman.
Abstract
OBJECTIVE: Little is known about the mental health outcomes of young children who experience developmental delay. The objective of this study was to assess whether delay in attaining developmental milestones was related to depressive and anxious symptoms in adolescence.Entities:
Mesh:
Year: 2013 PMID: 23437245 PMCID: PMC3577691 DOI: 10.1371/journal.pone.0056804
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Descriptive information for sample.
| Characteristic | Weighted Percentage/Weighted Mean (SD) |
| Age in Months | 35.99 (6.73) |
| Cycle (Two) | 48.39% |
| MSD Score (Continuous; Overall) | 100.31 (14.36) |
| MSD Score (Continuous; 2 Year Olds) | 100.10 (14.19) |
| MSD Score (Continuous; 3 Year Olds) | 100.51 (14.52) |
| Gender (male) | 51.02% |
| SES (mid) | 7.38% |
| SES (high) | 74.69% |
| Race (White) | 88.51% |
| Family Type (intact) | 82.25% |
| Family Type (not intact) | 6.44% |
| Gestational Age (Days) | 272.93 (14.54) |
| Emotional Disorder/Anxiety Score | 3.39 (2.73) |
| Previous SLE (1) | 35.11% |
| Previous SLE (2 or more) | 26.75% |
| Recent SLE (1) | 29.22% |
| Recent SLE (2 or more) | 4.20% |
Weighted distribution of anxious/depressed symptoms.
| No Symptoms | Mild | Moderate | Severe | |
| Delay | 39.61% | 24.69% | 28.59% | 7.11% |
| No Delay | 44.49% | 24.62% | 23.07% | 7.82% |
Association between delayed milestone attainment at age 2–3 and symptoms of depression and anxiety in adolescence.
| Males | Females | Overall | |
| Crude |
| 1.49 (0.90–2.49) | 1.20 (0.91–1.57) |
| Adjusted |
| 1.42 (0.86–2.35) |
|
| Adjusted |
| 1.46 (0.87–2.48) |
|
Adjusted for gender, SES and cycle (with the exception of gender in analyses stratified by gender).
Adjusted for gender, race, SES, family type, gestational age and cycle (with the exception of gender in analyses stratified by gender).
p<0.05.
Association between categories of developmental milestones and depressive symptoms in adolescence.
| Males | Females | Overall | |
|
| |||
| Crude |
| 1.05 (0.87–1.27) | 1.08 (0.98–1.19) |
| Adjusted |
| 1.07 (0.88–1.30) |
|
| Adjusted |
| 1.09 (0.89–1.33) |
|
|
| |||
| Crude |
|
|
|
| Adjusted |
|
|
|
| Adjusted |
|
|
|
|
| |||
| Crude | 1.10 (0.97–1.24) | 1.06 (0.91–1.23) | 1.06 (0.96–1.18) |
| Adjusted | 1.07 (0.92–1.25) | 1.12 (0.94–1.32) | 1.08 (0.97–1.22) |
| Adjusted | 1.07 (0.92–1.25) | 1.13 (0.95–1.34) | 1.10 (0.98–1.23) |
|
| |||
| Crude | 1.18 (0.87–1.60) | 0.96 (0.74–1.25) | 0.94 (0.78–1.14) |
| Adjusted | 1.12 (0.79–1.58) | 0.99 (0.75–1.32) | 1.04 (0.84–1.29) |
| Adjusted | 1.06 (0.76–1.50) | 0.99 (0.74–1.32) | 1.03 (0.83–1.28) |
Adjusted for gender, age in months, SES and cycle (with the exception of gender in analyses stratified by gender).
Adjusted for gender, age in months, race, SES, family type, gestational age and cycle (with the exception of gender in analyses stratified by gender).
p<0.05.
p<0.01.
p<0.001.